Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 2/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
| ▸ | GABRE | P78334 | 1/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768561 | 1.00 | ELANE (0.33) | ELANECYP2E1CYP2A6CHRNB2CHRNA4 | |
| SCHEMBL23457989 | 0.80 | ELANE (0.36) | ELANECYP2E1CYP2A6CHRNB2CHRNA4 | |
| SCHEMBL29768504 | 0.78 | KCNH2 (0.31) | GRM5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL23458075 | 0.78 | KCNH2 (0.31) | GRM5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL23481079 | 0.77 | RXRA (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL29768520 | 0.73 | GRIN2D (0.32) | GRM5 | |
| SCHEMBL23457996 | 0.73 | GRIN2D (0.32) | GRM5 | |
| SCHEMBL23481288 | 0.72 | GRM5 (0.32) | GRM5 | |
| SCHEMBL23481304 | 0.71 | CYP2E1 (0.44) | ELANECYP2E1CYP2A6CHRNB2CHRNA4 | |
| SCHEMBL23458100 | 0.68 | ALDH1A1 (0.43) | ELANECYP2E1CYP2A6CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528784-B2 | Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4069685-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-10-12 | — | — | EP | disclosed |
| US-20220306607-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2022-09-29 | — | — | US | disclosed |
| CN-114746408-A | Alkynyl- (heteroaryl) -carboxamide HCN1 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021110574-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110574-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528784-B2 | Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors | HCN1, HCN2, HCN3 | ELANE 2173/4885CYP2E1 97/4885CYP2A6 58/4885 |
| US-20220306607-A1 | ALKYNYL-(HETEROARYL)-CARBOXAMIDE HCN1 INHIBITORS | HCN1, HCN2, HCN3 | ELANE 3489/4885CYP2E1 65/4885CYP2A6 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.